Cambridge, Mass., Dec 04 — Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independent director. Mike Bonney and Carolyn Bertozzi, Ph.D., who have served in key roles on Alnylam’s Board, stepped down effective December 2, 2025.
Mr. Bonney joined our Board in 2014 and served as Board Chair from December 2015 to August 2021 and as Executive Chair from August 2021 to January 2023. He helped to guide the company through major milestones and significant growth, including the approval and launch of multiple RNAi therapeutics, delivery of a flagship franchise, and tremendous pipeline expansion. Mr. Bonney served as a Class I director, and his term was due to expire at the upcoming 2026 annual meeting of stockholders.
Dr. Bertozzi joined the Board in 2023 and has served as a member of the Nominating and Corporate and Science and Technology Committees and our Scientific Advisory Board. In her time, she has provided impactful scientific oversight and advice to our teams during a key period of growth and pipeline expansion for the company. Dr. Bertozzi’s decision to resign from the Alnylam Board follows her recent election to the board of Eli Lilly, effective December 8, 2025. She will continue to serve as a scientific advisor to Alnylam.
“We are deeply grateful to Mike and Carolyn for their leadership, strategic insight, and unwavering commitment to Alnylam’s mission,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “Their contributions have helped shape Alnylam into the global R&D and commercial leader it is today. We thank them for their service and wish them the very best in their future endeavors.”
Alnylam also announced the appointment of Stuart Arbuckle to its Board of Directors, effective as of January 5, 2026. Mr. Arbuckle brings extensive experience in biopharmaceutical commercialization and leadership from companies such as GSK and Amgen. He spent the last 13 years at Vertex, most recently as Executive Vice President and Chief Operating Officer. At Vertex, he was responsible for Global Commercial Operations, Human Resources, Corporate Communications and Portfolio and Program Management. Mr. Arbuckle played a pivotal role in growing and globally scaling Vertex’s business.
Mr. Arbuckle currently serves as a member of the board of directors at Rhythm Pharmaceuticals.
“We are delighted to welcome Stuart to our Board,” said Amy Schulman, Chair of the Alnylam Board of Directors. “He brings a valuable combination of commercial expertise and commitment to scientific innovation that will support our next phase of growth as we continue advancing RNAi therapeutics for patients worldwide. I join Yvonne in thanking Mike and Carolyn for their contributions.”
Mr. Arbuckle added, “I am honored to join Alnylam’s Board at such an exciting time and important inflection point for the company. I look forward to working with management and fellow directors as the company continues to sustainably grow while pioneering transformative medicines.”
These Board changes will support Alnylam’s ongoing strategic evolution as it advances a robust pipeline across rare and prevalent diseases, expands its global reach, and continues to execute on its vision of building a top-tier, multi-product biotechnology company.